Notice of 38th Annual General Meeting of the Company
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bacil Pharma Limited has issued the notice for its 38th Annual General Meeting (AGM) scheduled for Monday, September 29, 2025 at 1:00 p.m. IST, to be conducted via Video Conferencing (VC) / Other Audio-Visual Means (OAVM), with e-voting facilitated by NSDL from September 26 to September 28, 2025. Shareholders will vote on 10 resolutions, including adoption of FY2024-25 audited financial statements, re-appointment of Ms. Chaitali Kalpataru Shah as Executive Director, and appointment of Ms. Vivek Mukesh Yadav as Independent Director for a 5-year term (Aug 25, 2025 to Aug 24, 2030). The company proposes to replace its statutory auditor M/s Laxmikant Kabra & Co LLP with M/s Sarang Shivajirao Chavan & Associates to fill a casual vacancy, and appoint M/s Ramesh Chandra Bagdi & Associates as Secretarial Auditor for 5 years. Key capital-related resolutions seek shareholder approval for raising investments/loans/guarantees up to ₹100 crore, overall borrowing limits of ₹100 crore under Section 180(1)(c), and loans up to ₹50 crore with an option to convert into equity shares.
Shareholders should pay attention to the promoter reclassification (which moves certain entities from promoter to public category) and the ₹50 crore loan-to-equity conversion resolution, as it carries potential equity dilution risk. The increased borrowing/investment limits of ₹100 crore and the change in statutory auditors also signal notable governance and capital structure shifts worth monitoring ahead of the September 29, 2025 AGM.